open access

Vol 18, No 5 (2013)
Reviews
Published online: 2013-09-01
Submitted: 2013-01-23
Get Citation

Tamoxifen in breast cancer in uterine malignant mixed Müllerian tumor and sarcoma—A report of 8 cases and review of the literature

Ana Luisa Vasconcelos, Beatriz Nunes, Catarina Duarte, Vera Mendonça, Joana Ribeiro, Marília Jorge, Isabel Monteiro Grillo
DOI: 10.1016/j.rpor.2013.06.005
·
Rep Pract Oncol Radiother 2013;18(5):251-260.

open access

Vol 18, No 5 (2013)
Reviews
Published online: 2013-09-01
Submitted: 2013-01-23

Abstract

Aim

Report the outcome of 8 patients (pts) with breast cancer (BC) treated with Tamoxifen (TAM) that developed malignant mixed Müllerian tumor (MMMT) and rare uterine sarcoma (RUS).

Patients and methods

Retrospective study based on data collected from the department medical records between April 1999 and September 2010 among 583 pts with endometrial cancer, 36 pts with MMMT and RUS histopathology. Among them, 8 pts underwent TAM between 4 and 10 years due to a previous diagnosis of BC; all pts were post-menopausal with regular gynecological surveillance; 6 pts (75%) with abnormal uterine bleeding. The diagnosis of 6 pts (MMMT) and 2 pts (RUS) occurred at median interval of 8 years (range 4–12) after initial BC treatment. Pts underwent surgical treatment and were staged as stage I (3pts), IIIA (3pts) and IIIC (2 pts) (FIGO 1988); followed by whole pelvis irradiation (50[[ce:hsp sp="0.25"/]]Gy) and intracavitary HDR brachytherapy boost (24[[ce:hsp sp="0.25"/]]Gy). Two pts underwent chemotherapy (CT). Overall and disease free survival was calculated by Kaplan Meier method.

Results

With a median follow-up of 47 months (range 17–130), 3 pts remain alive recurrence-free of BC and RUS. Four pts died with distant metastasis within the first follow-up year, without BC. One pt died from non-related cancer cause. No evidence of local recurrence was found in the whole group of pts. At two years, DFS and OS were 40% and 80%, respectively.

Conclusion

As reported in the literature, TAM administration and causal effect on MMMT and RUS in BC pts is still unknown. No reports about outcome from these specific pts were found.

Abstract

Aim

Report the outcome of 8 patients (pts) with breast cancer (BC) treated with Tamoxifen (TAM) that developed malignant mixed Müllerian tumor (MMMT) and rare uterine sarcoma (RUS).

Patients and methods

Retrospective study based on data collected from the department medical records between April 1999 and September 2010 among 583 pts with endometrial cancer, 36 pts with MMMT and RUS histopathology. Among them, 8 pts underwent TAM between 4 and 10 years due to a previous diagnosis of BC; all pts were post-menopausal with regular gynecological surveillance; 6 pts (75%) with abnormal uterine bleeding. The diagnosis of 6 pts (MMMT) and 2 pts (RUS) occurred at median interval of 8 years (range 4–12) after initial BC treatment. Pts underwent surgical treatment and were staged as stage I (3pts), IIIA (3pts) and IIIC (2 pts) (FIGO 1988); followed by whole pelvis irradiation (50[[ce:hsp sp="0.25"/]]Gy) and intracavitary HDR brachytherapy boost (24[[ce:hsp sp="0.25"/]]Gy). Two pts underwent chemotherapy (CT). Overall and disease free survival was calculated by Kaplan Meier method.

Results

With a median follow-up of 47 months (range 17–130), 3 pts remain alive recurrence-free of BC and RUS. Four pts died with distant metastasis within the first follow-up year, without BC. One pt died from non-related cancer cause. No evidence of local recurrence was found in the whole group of pts. At two years, DFS and OS were 40% and 80%, respectively.

Conclusion

As reported in the literature, TAM administration and causal effect on MMMT and RUS in BC pts is still unknown. No reports about outcome from these specific pts were found.

Get Citation

Keywords

Breast cancer; Tamoxifen-related uterine sarcoma; Pelvic irradiation

About this article
Title

Tamoxifen in breast cancer in uterine malignant mixed Müllerian tumor and sarcoma—A report of 8 cases and review of the literature

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 18, No 5 (2013)

Pages

251-260

Published online

2013-09-01

DOI

10.1016/j.rpor.2013.06.005

Bibliographic record

Rep Pract Oncol Radiother 2013;18(5):251-260.

Keywords

Breast cancer
Tamoxifen-related uterine sarcoma
Pelvic irradiation

Authors

Ana Luisa Vasconcelos
Beatriz Nunes
Catarina Duarte
Vera Mendonça
Joana Ribeiro
Marília Jorge
Isabel Monteiro Grillo

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl